An observational study in Mechanical Ventilation and Patient-Ventilator Asynchrony, sponsored by Erasmus Medical Center. Recruiting at 3 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-13.
Sponsored by Erasmus Medical Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this observational study is to unravel the occurence, impact and relations of Patient-Ventilator Aynchrony (PVA) in mechanically ventilated patients. The main questions it aims to answer are:
All questions will be assessed using data collected during the whole course of mechanical ventilation. Mechanically ventilated patients' medical data will be re-used. PVAs will be automatically classified on ventilator waveform data, using validated Deep Breath software.
Many ventilated patients show excessive breathing efforts and abnormal, irregular breathing. This patient-ventilator asynchrony (PVA) is associated with serious discomfort, lung injury, sleep disruption and higher mortality. PVA exists in many forms and is reported in 10-90% of patients, but identifying and resolving it is challenging, even for expert clinicians. Hence, PVA prevalence and impact is likely highly underestimated, and the direct causal link with worse outcomes is inconclusive. PVAs should be better dettected, understood and resovled to optimize the individual patient's treatment.
In a previous study, the investigators validated an AI-based algorithm capable of reliable PVA detection (Deep Breath software). In this study, the investigators will apply this algorithm to the collected ventilator waveform data (offline processing), in order to reliably assess PVA occurrence, and its relation with clinical outcomes and patient characteristics in current clinical care. Data of minimally 110 patients collected over the whole course of mechanical ventilation will be assessed. Patients will be included in three ICUs to promote generalizability.
The primary outcome will be the asynchrony index (in total and per PVA type) over time. Secondary outcomes will include, but are not limited to: clinical characteristics (e.g. respiratory and hemodynamic parameters, sedation), (ICU) mortality, ventilator free days at day 28 and 90, duration of ventilation, weaning success and reintubation rate.
24 studies on the registry are indexed under Patient-Ventilator Asynchrony; 11 are open to participants now.
This study's planned enrollment of 110 is above the median of 40 across 13 observational studies indexed under Patient-Ventilator Asynchrony.
Browse Patient-Ventilator Asynchrony studies →Erasmus Medical Center is the lead sponsor of 479 studies on the registry; 182 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adult patients admitted to the ICU that receive invasive mechanical ventilation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients need to be \>18 years old, receive mechanical ventilation for at least 24 hours and have recordings available of ventilator waveforms, synchronized with the patient's electronic health record, during invasive mechanical ventilation.
Other: PVA classification software
Patients will receive standard care, without an intervention. Data will be captured as part of standard care and analyzed for PVAs retrospectively, using dedicated offline software.
Asynchrony index over time (aggregated and per PVA type)
Measure of how much asynchrony occurs and at what time. This measure will be calculated for all PVA types together, as well as per PVA type. The investigators calculate this over time, to see when asynchrony occurs, as well as in total, to get a global PVA prevalence measure (over the whole duration of ventilation).
Time frame: 28 days
Use of sedatives (cumulative dose and type)
Time frame: 28 days
Mechanical ventilation settings
Time frame: 28 days
Respiratory parameters
Time frame: 28 days
Hemodynamic parameters
Time frame: 28 days
Relevant medication
e.g. vasoactive agents, delirium related medication, analgesics
Time frame: 28 days
Use of assist devices
e.g. dialysis, pacemaker, ventricular assist device, ECMO
Time frame: 28 days
Gas exchange parameters
e.g. P/F ratio, PaO2, PaCO2, pH, bicarbonate
Time frame: 28 days
Blood inflammatory biomarkers
upon availability in the patient's electronic chart, e.g. CRP, lactate
Time frame: 28 days
Sedation depth
Richmond Agitation-Sedation Scale (RASS-score). This score ranges from -5 to +4, where a more positive score indicates more agitation.
Time frame: 28 days
Reported delirium
Reported delirium, observed via the Delirium Observation Screening (DOS), or the Intensive Care Delirium Screening Checklist (ICDSC), depending on the standard of care of the participating center. The DOS ranges from 0-13, with a score ≥3 indicating delirium. The ICDSC ranges from 0-8, with 0-3 indicating absence of delirium and a score of ≥4 inidicating delirium.
Time frame: 28 days
Illness severity score (SOFA-score)
SOFA-score. This score ranges from 0-24, with increasing scores reflecting more abnormal physiology and biochemistry or an increasing degree of intervention.
Time frame: 28 days
ICU mortality
Mortality during ICU stay
Time frame: 90 days
Mortality at day 28
Mortality at day 28
Time frame: 28 days
Mortality at day 90
Mortality at day 90
Time frame: 90 days
Duration of ventilation
Duration of ventilation in hours or days
Time frame: 28 days
Ventilator free days (at day 28)
Number of ventilator free days at day 28
Time frame: 28 days
Ventilator free days (at day 90)
Number of ventilator free days at day 90
Time frame: 90 days
Reintubation rate
Number of times reintubation occured, reported as % of patients needing reintubation.
Time frame: 28 days
Weaning success
Weaning success rate (%), defined as seven consecutive days without ventilator support
Time frame: 28 days
ICU length of stay
Length of ICU stay, measured in days
Time frame: 28 days
Complications
Complications (e.g. ventilator associated pneumonia and ICU acquired weakness) as reported in the patient file.
Time frame: 28 days
Plan to share: Yes — The final dataset will be available on reasonable request, with removed/anonymized timestamps for pseudonimization. The request will be reviewed by the PI, depending on the topic/quality of the proposal and including a plan for publication/authorship, and ensuring that the request meets legal and organizational requirements. Sharing of data for reuse by third parties will always only involve de-identified datasets and via a data transfer agreement.
Supporting information: Study protocol, Clinical study report, Analytic code
Time frame: IPD will be available after publication of the Clinical Study Report. IPD will be available for 10 years, in compliance with Dutch laws.
Started Jul 2026 (actual). Primary completion is estimated for Nov 2026, 4 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Patient-Ventilator Asynchrony →